A highly automated 5 pump, 4 detector super-critical fluid chromatography (SFC) mass spectrometry (MS) system for purification in drug discovery

Similar documents
Chiral Multicolumn Method Development on the Agilent 1260 Infinity II SFC System

QuickSplitTM Flow Splitters

Automated Purification and Analytical Reinjection of a Small Molecule Drug, Probenecid, on a Gilson LC/MS Dual Function System

Optimizing Chiral Separations and Purification of Enantiomers Through Selective Sample Slicing and Column Switching

Mass-Based Purification of Natural Product Impurities Using an Agilent 1260 Infinity II Preparative LC/MSD System

Small Scale Preparative Isolation of Corticosteroid Degradation Products Using Mass-Based Fraction Collection Application

10 mg in 1.4 ml. XTerra MS C 18, 4.6 x 50 mm. Volume injected: Injector Column. Waste. Pump. Pump. Splitter

Chiral Screening for SFC and UHPLC with the Agilent 1260 Infinity II SFC/UHPLC Hybrid System

Comparison of a UPLC Method across Multiple UHPLC Systems

Determination of enantiomeric purity of Timolol Maleate by Supercritical Fluid Chromatography

Agilent 1260 Infinity Analytical SFC System

Edgar Naegele. Abstract

High-Resolution Analysis of Intact Triglycerides by Reversed Phase HPLC Using the Agilent 1290 Infinity LC UHPLC System

2D-LC as an Automated Desalting Tool for MSD Analysis

Application Note. Introduction

QuickSplit TM Flow Splitters

Rapid Gradient and Elevated Temperature UHPLC of Flavonoids in Citrus Fruit

Single Quadrupole Compact Mass Spectrometer for Liquid Sample

Lipidomic Analysis by UPLC-QTOF MS

Rapid and sensitive UHPLC screening of additives in carbonated beverages with a robust organic acid column

Achiral SFC: Development of an Orthogonal SFC Method for Mometasone Furoate Impurity Analysis

Dr. Erin E. Chambers Waters Corporation. Presented by Dr. Diego Rodriguez Cabaleiro Waters Europe Waters Corporation 1

Robust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS

Ultra High Performance Liquid Chromatograph. Nexera X2 C196-E079

Ultra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification

A Robustness Study for the Agilent 6470 LC-MS/MS Mass Spectrometer

LC/MS/MS Separation of Cholesterol and Related Sterols in Plasma on an Agilent InfinityLab Poroshell 120 EC C18 Column

Increasing resolution using longer columns while maintaining analysis time Advantages of the wide power range of the Agilent 1290 Infinity LC System

EASIMIP TM PATULIN Product Code: P250 / P250B

Identification of Steroids in Water by Ion Trap LC/MS/MS Application

Maximizing chromatographic peak capacity with the Agilent 1290 Infinity LC system

Determination of 6-Chloropicolinic Acid (6-CPA) in Crops by Liquid Chromatography with Tandem Mass Spectrometry Detection. EPL-BAS Method No.

Comprehensive Two-Dimensional HPLC and Informative Data Processing for Pharmaceuticals and Lipids

Effective use of Pharmacopeia guidelines to reduce cost of chromatographic analysis for Fluticasone propionate

Impurity Identification using a Quadrupole - Time of Flight Mass Spectrometer QTOF

Agilent 1260 Infinity Analytical Hybrid SFC/UHPLC system

Journal of Chemical and Pharmaceutical Research

Application Note. Small Molecule Pharmaceuticals. 2-Ethyl-2-phenylmalonamide Ethosuximide Primidone Carbamazepine. Carbamazepine-

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column

Rapid and sensitive UHPLC screening for water soluble vitamins in sports beverages

Supercritical Carbon Dioxide Extraction of Lignan from Cold-Press By-product of Sesame Seed

Using Hydrophilic Interaction Chromatography (HILIC) for the Retention of Highly Polar Analytes

Fast Separation of Triacylglycerols in Oils using UltraPerformance Convergence Chromatography (UPC 2 )

Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Application Note. Agilent Application Solution Analysis of ascorbic acid, citric acid and benzoic acid in orange juice. Author. Abstract.

Choosing Preparative Columns

LCMS Vitamin D3 Method development

Fast determination of residual glycerol and glycerides in biodiesel by SFC/MS using the Agilent 1260 Infinity Analytical SFC System

Analysis of HMF by HPLC

DIRECT EXTRACTION OF BENZODIAZEPINE METABOLITE WITH SUPERCRITICAL FLUID FROM WHOLE BLOOD

The HPLC Preparative Scale-Up of Soybean Phospholipids Application

MS/MS Library Creation of Q-TOF LC/MS Data for MassHunter PCDL Manager

A RAPID AND SENSITIVE UPLC/UV/MS METHOD FOR SIMVASTATIN AND LOVA S TAT IN IN SU P P O RT O F C L E A NING VA L I DAT IO N S T U DIES

Measuring Lipid Composition LC-MS/MS

Isolation of five carotenoid compounds from tangerine tomatoes

Analysis of Antioxidants in Vegetable Oils Using the Agilent 1260 Infinity Hybrid SFC/UHPLC System with MS Detection

Sample Concentration and Analysis of Human Hormones in Drinking Water

[ APPLICATION NOTE ] The Separation of 8 -THC, 9 -THC, and Their Enantiomers by UPC 2 Using Trefoil Chiral Columns INTRODUCTION APPLICATION BENEFITS

A Validated Chiral Liquid Chromatographic Method for The Enantiomeric Separation of Dapoxetine Hydrochloride

Application Note. Authors. Abstract. Petrochemical

Protein Precipitation for Biological Fluid Samples Using Agilent Captiva EMR Lipid 96-Well Plates

SUPPLEMENTARY DATA. Materials and Methods

Method Development for the Analysis of Endogenous Steroids Using Convergence Chromatography with Mass Spectrometric Detection

Introduction to the Oligo HTCS Systems. Novatia, LLC

High-Throughput Analysis of Oligonucleotides using Automated Electrospray Ionization Mass Spectrometry

Quantitative Analysis of Underivatized Amino Acids in Plant Matrix by Hydrophilic Interaction Chromatography (HILIC) with LC/MS Detection

Applications Summary Waters Corporation 1

METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE

Analytical Method Development for USP Related Compounds in Paclitaxel Using an Agilent Poroshell 120 PFP

LC/MS Method for Comprehensive Analysis of Plasma Lipids

Mass Spectrometry at the Laboratory of Food Chemistry. Edwin Bakx Laboratory of Food Chemistry Wageningen University

Automated Sample Preparation/Concentration of Biological Samples Prior to Analysis via MALDI-TOF Mass Spectroscopy Application Note 222

Application Note. Abstract. Authors. Pharmaceutical

Am I getting the very best value from my UHPLC analyses?

Extended Application Note

Mass Directed Flash Chromatography by Biotage. Biotage Dalton Mass Detectors

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:

Product Guide for LudgerSep TM R1 HPLC Column for DMB labelled Sialic Acid Analysis

LC-MS/MS Method for the Determination of Tenofovir from Plasma

Cannabinoid Profiling and Quantitation in Hemp Extracts using the Agilent 1290 Infinity II/6230B LC/TOF system

Quantitative Analysis of Vit D Metabolites in Human Plasma using Exactive System

PHOTOCATALYTIC DECONTAMINATION OF CHLORANTRANILIPROLE RESIDUES IN WATER USING ZnO NANOPARTICLES. DR. A. RAMESH, Ph.D, D.Sc.,

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

Sepax Technologies, Inc.

Profiling of Endogenous Metabolites Using Time-of-Flight LC/MS with Ion Pair Reverse Phase Chromatography

The Raptor HILIC-Si Column

Performance characteristics of the Agilent 1100 Series preparative pump. Technical Note. Abstract

Measuring Phytosterols in Health Supplements by LC/MS. Marcus Miller and William Schnute Thermo Fisher Scientific, San Jose, CA, USA

Thermo Scientific. GlycanPac AXR-1. Column Product Manual. P/N: April, Part of Thermo Fisher Scientific

A New Era in SFC Column Technology

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC

A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms

Analysis of Vitamins Using an SFC/UHPLC Hybrid System with a Triple Quadrupole LC/MS for Quantification

F. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract

Integration of steroids analysis in serum using LC-MS/MS with full-automated sample preparation

Removal of Triton X-100 from Plasma Samples Using Mixed-Mode Solid Phase Extraction (SPE)

Probing for Packaging Migrants in a Pharmaceutical Impurities Assay Using UHPLC with UV and Mass Detection INTRODUCTION

Transcription:

A highly automated 5 pump, 4 detector super-critical fluid chromatography (SFC) mass spectrometry (MS) system for purification in drug discovery A new system that is a work in progress, but we have initial data to show Qing Ping Han and Mark J. Hayward* Lundbeck Research USA 215 College Rd. Paramus, NJ 07652

Outline Rationale and progress Why SFC/MS Business objectives Instrument design Instrument features Separation examples Chiral Achiral Summary of the experience thus far

We bought our system to meet chiral needs: Why use chiral separations? In drug discovery, many compounds are chiral In some cases, individual enantiomers have unique and valuable biological properties In vitro and in vivo biological tests need to be performed using individual enantiomers, so that the stereo specific biological properties of drug candidates can be measured Often, chiral resolution is most efficiently achieved using column chromatography Reviews on the medical benefits of chirality in pharmaceuticals: I. Agranat, H. Caner, J. Caldwell, Nat. Rev. Drug Discov., 1, 2002, 753. H. Caner, E. Groner, L. Levy, I. Agranat, Drug Discov. Technol., 9(3), 2004, 105.

Why use super-critical fluid chromatography mass spectrometry (SFC/MS) system? SFC can be used with modifier (normally MeOH) gradient to perform generic gradient separation of wide range of compounds (including polar ones) in a way that is generally complementary with RP-LC. SFC is generally the best way to perform generic gradient elution for normal phase separations (sufficiently broad composition range). Most of the best chiral columns work best in normal phase. SFC is faster and has better loading than NP-LC. (of which we do a lot) SFC is MS compatible. This is a crucial efficiency component because it permits collection of only the particular desired peaks. Use of CO 2 as solvent is less expensive than liquid solvents. Fractions are conveniently (and efficiently) obtained in a minimal volume of modifier for easy recovery of purified compounds, with no water in fractions minimizing evaporation bottleneck and saving energy. In our hands, chiral method development takes the least number of injections when using gradient SFC to screen column and mobile phase conditions. Early efforts in preparative SFC/MS with open bed collection: T. Wang, M. Barber, I. Hardt, D.B. Kassel, Rapid Comm.Mass Spectrom., 15, 2001, 2067. X. Zhang, M.H. Towle, C.E. Felice, J.H. Flament, W.K. Goetzinger, J. Combin. Chem., 8, 2006, 705.

Business objectives for our gradient SFC/MS based chiral purification platform Routinely inject 100 mg and yield 10 g per day (1g/hr) of high purity (95-99% ee) for any number of chiral compounds (1-20) with >99% success rate (crucial for achieving trust, throughput and fast turnaround) Where desired, achiral purification of 100 compound parallel synthesis libraries (generally, when there is a need that can t be readily solved with LC/MS based purification) Flow 100g/min Open bed collection under atmospheric conditions to simplify process and enhance safety (must be safe and efficient) Ease of operation, use same equivalent LC/MS software to reduce labor on operation and learning curves (MassLynx / FractionLynx) Informatics: main stream software platform to ensure minimal workload on data handling and integration for efficient process (NuGenesis SDMS, crucial for transparency and trust)

Much of our SFC design philosophy comes from our established approach toward RP-LC/MS based purification RP-LC/MS Purification System Schematic All components under full software control (MassLynx V4.1) [except automatic heaters] Back-flush regenerating pump Back-flush solvent selections (ACN, 5% acetic acid and DMF) MS Photo diode array ELSD heater Makeup pump splitter Fraction collector 6-pos. column selectors choose up to 6 column chemistries Injection port heater SunFire C18 XBridge C18 Inertsil C8 Inertsil C18 Column water bath Dilution solvent selections (ACN, 50/50 ACN water mixture, etc..) At column dilution pump Waste level sensor and auto switcher Waste UV heater mixer Concentrated buffers at 1-4 M: NH 4 COOH, NH 4 COOCH 3, CH 3 COOH, NH 3, H 2 Oetc Concentrated buffer pump Waste barrels B A Binary pump Degassers Acetonitrile MilliQ Gradient water purification and autodelivery system 1

Planned SFC/MS Purification System Schematic All components under full software control (MassLynx V4.1) Back flush/regeneration P50 CO 2 + P50 Modifier (awaiting software) heater AD OD 515 515 AS Splitter OJ Photo diode Array-2996 heater 6-pos. column selectors choose up to 6 column chemistries Dilution solvent selections (alcohols, 50/50 alcohols and CO 2 mixture, etc..) MS-ZQ ELSD-2420 Fraction collector Injection port heater At column dilution pump (Thar analytical FDM) (awaiting software) Waste level sensor and auto switcher Waste UV (2487) SIII Make up pump G L S heater mixer PR 40 PSI CO 2 vent Diethylamine, triethylamine, isopropylamine, ammonium formate, formic acid etc in alcohols Concentrated buffer pump (515) (awaiting software) P-200 CO 2 P-200 modifier G700 with Bulk Tank Waste barrels Degassers Alcohols All components implemented except P50(x2), FDM, and third 515 pump

Instrument photo

Instrument photo

CO 2 Source Photos House CO 2 we do nothing but use it

Key components of the SFC/MS purification system Gas-Liquid Separator (GLS) The flow stream passes back pressure regulator at this point Depressurization of CO 2 occurs at this step The significantly increased volume of gaseous CO 2 needs to be dealt with, rather than letting it flow into collection tubes, which will cause all sorts of problems. GLS: Minimal CO 2 at collection tip Most gaseous CO 2 is vented from the top of GLS Aerosols usually accompanied with this process is mostly eliminated and/or effectively controlled. This ensures minimal sample loss and enhanced safety GLS: smooth flow into collector The residual liquid flow is guided through the bottom of the chamber to open-bed fraction collector. Separation pump adjusts with separation gradient to maintain steady liquid flow through the GLS. Works surprisingly well. Open-Bed collection Collecting in same tubes/racks used in LC to ensure safety and eliminate complexity for otherwise required customized collection design, workload and cost is lowered significantly, and system robustness is enhanced by ease of operation (collecting into EPA tubes - 27 x 100 mm)

Effect of separation temperature on carbamazpine peaks carbamazepine-4 5.0 30 o C 2.25 40 o C 50 o C 2: Diode Array 230 Range: 5.515 4.0 3.0 2.0 1.0 Time 2.10 2.15 2.20 2.25 2.30 2.35 2.40 2.45 2.50 Peak shape doesn t change much with increasing temperature compared with RP HPLC separations. Also, the effects can be counter-intuitive (RT increasing with increasing T opposite expected). However, temperature can still be very helpful with selectivity (see next).

Temperature tuning the separation Temperature can dramatically enhance selectivity, sometimes in unexpected ways A B C D Mixture of endo/exo confirmations and R/S isomers at (A) 30, (B) 40, (C) 50, and (D) 60 C

Mobile phase without buffering Effect on peak shape as a function of loading 50 mg impramine-6 2.75e-1 2.53 100 mg 2: Diode Array 320 Range: 2.192e-1 2.5e-1 2.25e-1 25 mg 2.0e-1 1.75e-1 1.5e-1 Imipramine 1.25e-1 1.0e-1 7.5e-2 5.0e-2 2.5e-2 Time 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 when loading increases, peak shape suffers

Mobile Phase Buffering Controlling separation under high mass loading 100 m g, 5% to 20% M EOH+0.2% DEA, 100 G/MIN, bp120, sp 300,40oC im pram ine-8 2.91 2.75e-1 2.5e-1 2.25e-1 2.0e-1 No additive 0.2% DEA Imipramine 2: Diode Array 320 Range: 3.736e-1 A U 1.75e-1 1.5e-1 1.25e-1 1.0e-1 7.5e-2 5.0e-2 2.5e-2 Time 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 Buffering can help a lot with peak shape under high loading conditions SFC peak shape becomes much better with adding 0.2%DEA in MeOH. We believe adding a 515 pump & 6-way valve will add significant value by allowing method selection of 6 buffer choices and their concentrations in the separation approach proven in RP-LC/MS based systems

Added Automation Features: Waste UV chromatogram Of course, useful in setting collection delay parameters Waste UV chromatogram to show compound was collected (not lost). This helps eliminate time consuming discussions about where did all my compound go? I know I had xxx mg! Convincing nature of data presentation minimizes need for post purification QC for ordinary compounds (95% purity threshold cmpds, i.e. libraries). Sample Report: Sample 195 Vial 5,1:1 ID 22100-090-001 File 4 mixture-t5 Date 07-Jul-2009 Time 16:17:55 Description QPH 2: UV Detector: TIC 4.0e+2 2.0e+2 1: MS ES+ :237+238+259 % 100 75 50 25 0 WasteUV_2487 % 100 75 50 1.85 2.29 a 4.23 3.36 0 1.00 2.00 3.00 4.00 5.00 6.00 2.27 a 0 1.00 2.00 3.00 4.00 5.00 6.00 25-0.28 0 1.84 a 3.35 4.24 6.36 5.84 6. 5.32 0 1.00 2.00 3.00 4.00 5.00 6.00

Added Automation Features: ELSD collected mass estimation Sample Report: ELSD Characteristics 2: UV Detector: TIC 6.0e+2 4.0e+2 1.90 2.55 6.064e+2 Range: 6.064e+2 Sample 244 Vial 5,1:1 ID 22100-089-016 File an-noc Date 13-Jul-2009 Time 13:58:29 Description analytical Mass based detection (not concentration) Fairly analyte independent +/- 20% accuracy readily achievable Automated inclusion in FractionLynx report 2.0e+2 Time 0 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 1: MS ES+ :189+190+211 % ELSD_2420 % 100 75 50 25 100 1.90 1.3e+008 0 Time 0 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 75 50 1.91 2.57 5.7e+004 25 0.81 0.90 0.44 1.26 1.55 2.22 3.15 3.39 3.66 3.94 0 Time 0 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 Time Amount [ mg ] 1.91 24 2.57 15 We still need to test extent that variable split is affecting calibration and accuracy (If so, we could switch to the usual 10000/1 split with 100 fold dilution)

Various separation examples: A. Chiral B. Achiral

Chiral

Example 1: Flurbiprofen on AD column (well known chiral example, loading test for instrument installation) 100 mg, 5 to 30 % MEOH, 100 G/MIN, bp120 sp 280,40oC flurbiprofen-t7 2.71 3.36 4.0 2: Diode Array 250 Range: 5.515 2.0 flurbiprofen-t6 4.0 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 2: Diode Array 2.76 3.46 250 Range: 5.512 2.0 flurbiprofen-t5 4.0 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 2: Diode Array 1.97 2.57 250 Range: 5.341 2.0 Time 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 Top and middle: 100 mg and 50 mg/injection with 5 to 40% MeOH in 5 min gradient; bottom: 50mg/injection and 15% MeOH with isocratic 100g/min and 30x150 mm AD-H column, BP 120 bar

Example 2: Separation and purification of an enantiomeric mixture by prep SFC/MS (in-house compound) 10 to 40% IPA, AD 2x25,80g/m in, bp120,sp258 AF19670-15 Sm (M n, 3x2) 2.34 2: Diode Array 254 Range: 7.097e-1 5.0e-1 2.5e-1 3.69 20% IPA 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 AF19670-16 Sm (M n, 3x2) 2: Diode Array 3.35 254 6.0e-1 Range: 6.994e-1 4.29 4.0e-1 2.0e-1 10 to 40% IPA in 5 min Tim e 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 A D, 2 0 % IP A, 3 5 o C, 1 2 0 b p AF19670-PK1b 2.65 2: Diode Array 250 Range: 2.344e-1 1.5e-1 1.0e-1 Analytical analysis of fraction 1 and 2 5.0e-2 3.14 5.14 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 AF19670-PK2b 4.51 2: Diode Array 250 Range: 1.422e-1 1.0e-1 5.0e-2 1.86 7.83 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Tim e Peak shape is better using gradient. ee is >99% for fraction 1 and 2 Condition: prep SFC AD, 20x250, 80g/min, bp120 bar Analytical SFC AD-H, 4.6x250, 4g/min, bp120 bar, 20%IPA

Example 3: Purification comparison of enantiomeric mixture by prep SFC/MS and NP HPLC (in house compound) AE94944- t5 S m (M n, 3 x 2) 1.75e-1 1.5e-1 1.25e-1 SFC, 10 to 40% MeOH, 80 g/min Loading: 20 mg 3.61 4.77 3 : Dio d e A rra y 254 Range: 2.048e-1 1.0e-1 7.5e-2 5.0e-2 AD-H 2x25 cm 5 µm In both cases 2.5e-2 Time 1.00 2.00 3.00 4.00 5.00 6.00 7.00 NP HPLC 5% IPA 95% Hexane 14ml/min Loading: 8 mg Under SFC conditions, baseline separation in 7 min. with single tube per peak, but NP-HPLC takes 30 min to separate enantiomers partially and requires collection in many tubes.

Example 4: Purification comparison of enantiomeric mixture on OJ and AS columns using prep SFC/MS (in-house compound) AE88128-t16 4.0e-1 OJ 20x250 4.18 5.63 2: Diode Array 254 Range: 4.074e-1 2.0e-1 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 AE88128-t10 Sm (Mn, 3x2) 2: Diode Array 3.43 254 Range: 1.455 1.0 5.0e-1 0.96 AS 20x250 1.21 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Time 8.00 4.32 OJ gives better separation under same SFC conditions SFC condition: 10 to 40% MeOH in 6 min, 80g/min, BP 120 bar 75 mg loading and single tube per peak collection

Example 5: Purification comparison of enantiomeric mixture by prep SFC/MS and NP HPLC (in house compound) NP-HPLC: cycle time 23min 40 mg/injection IA column - 2x25 cm, 5 um UV detection must fish out relevant tubes Resulting ee is 90% SFC/MS: cycle time 5 min 60 mg/injection. AD-H column - 3x15 cm, 5um UV & MS detection one peak desired, one tube collection Resulting ee is 100% 2.00 1.80 1.60 1.40 1.20 A U 1.00 0.80 0.60 0.40 0.20 0 2.00 4.00 6.00 8.00 10 12.00 14.00 16.00 18.00 20 Comparison: SFC is 7 fold more productive, far less laborious, and delivers higher quality!

Achiral SFC is the go-to technique for highly polar compounds particularly where the molecular differences are near the polar group(s)

Example 1: Separation covering diversity of samples, neutral, basic and acidic (well known standards easy stuff part of installation tests) 2.01 3.48 254 Range: 2.044 1.8 1.6 1.4 2.50 4.34 1.2 1.0 8.0e-1 6.0e-1 4.0e-1 2.0e-1 Time 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 Antipyrine, Carbamazepine, ketoprofen and sulfamethazine Conditions: flow 100 g/min, 5 40% MeOH @ 10%/min, 100 bar, ethylpyridine column, 30 x 150 mm 1 ml injection (100 mg, 25 mg of each)

Example 2: Separation of challenging basic drugs: desimipramine, imipramine and trimipramine (gives RP-LC/MS based approaches a real run for their money!) desipramine_impramine-trimi[ramine-2 2.39 2: Diode Array 230 Range: 5.454e-1 4.5e-1 4.0e-1 3.5e-1 3.0e-1 2.09 2.5e-1 2.0e-1 3.24 1.5e-1 1.0e-1 5.0e-2 Time 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 Peak 1 Trimipramine, peak 2 Imipramine, and peak 3 Desimipramine Conditions: flow 100 g/min, 5 40% MeOH @ 10%/min, 100 bar, ethylpyridine Column, 30 x 150 mm, 1 ml injection (100 mg ea)

Example 3: Purification comparison of reaction mixture by prep LC/MS and SFC/MS (in house compound) Prep RP-LC/MS can separate desired product and starting material under acidic conditions, but product peak is broad and split. m/z = 366 Prep SFC/MS can readily separate starting material (m/z = 258) and desired product (m/z = 366). Product peak is clean without nearby interferences. m/z = 366 m/z = 258 m/z = 258 TIC TIC While LC/MS works, SFC/MS looks like the way to go

Example 4: Purification comparison of reaction mixture by prep LC/MS and SFC/MS (in house compound) Prep LC/MS: desired product and starting material are partially co-eluted m/z = 364 Prep SFC/MS fully separates desired product (m/z = 364) from starting material (m/z = 288) m/z = 364 m/z = 288 m/z = 288 We couldn t get LC/MS to work. SFC/MS was straight forward.

Example 5: Purification of achiral product isomers by prep SFC/MS with chiral column (in house compound) AD-H, 3x15cm, 30:70 IPA/CO 2, 100g/min, 280 nm A mix of isomers (meta/para 55:44) 15:44:12 separated by SFC 250 04-Mar-2010 mg loading AF28962-1c Sm (Mn, 3x4) 2: Diode Array Complete co-elution with RP HPLC 230 Range: 5.078e-1 4.5e-1 4.0e-1 Time 3.24 6.49 Height 503336 204468 Area 72270.71 58490.75 Area% 55.27 44.73 3.5e-1 3.0e-1 2.5e-1 2.0e-1 1.5e-1 1.0e-1 5.0e-2 Time 0 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10 We couldn t get LC/MS to work. SFC/MS was straight forward.

Summary Our new Waters/Thar gradient SFC/MS based chiral purification platform has been setup for only short time and several promised components (pumps) have not yet been implemented. Nevertheless, preliminary results show that SFC100-MD-1 system works well for chiral and achiral separation and purification and is much better than NP HPLC in terms of efficiency (speed and loading). In many regards, our initial impression is that the system works better than we expected. 100 mg/injection has been achieved for both chiral and achiral purification. Analytical data of post purification fractions show that ee% is >99% for all enantiomers. We also have successfully implemented additional ELSD and UV detectors into the system. We believe that with addition components, on column dilution system with CO 2 and modifier, gradient back-flush system, separate buffer delivery sub-system, we will meet all our initial goals: routinely inject 100 mg and yield 10 g per day of high purity (95-99% ee) for any number of compounds (1-20) with >>99% success rate. With this new hardware, we will continue to experimentally push the envelope on purification production and performance. Of course, as progress is made, we will continue to report it.